

Dog Ownership: A Risk Factor for Corticosteroid Resistant Asthma?

FEBRUARY 26, 2007

DENVER —

Poster presentation by Pia Hauk, MD, February 26, 2007, at the annual meeting of the American Academy of Allergy, Asthma & Immunology

Presentation Time: Monday, 9:45 a.m. - 10:45 a.m.

P. J. Hauk, E. Goleva, A. H. Liu, C. F. Hall, R. J. Martin, D. Y. M. Leung;
National Jewish Medical and Research Center, Denver, CO.

RATIONALE: The cause of CR asthma is poorly understood. To identify new molecules that may be involved in steroid resistance, gene microarrays in airway macrophages from CR and corticosteroid-sensitive (CS) asthmatics were evaluated.

METHODS: Gene microarray analysis was performed in bronchoalveolar lavage (BAL) cells of CR and CS asthmatics. LPS levels in BAL fluid were measured by the limulus amoebocyte lysate test. Dog ownership was evaluated by questionnaire; dog allergy by skin prick test. Steroid response was assessed by LPS-induced TNF-alpha production by murine BAL macrophages (24h).

RESULTS: Microarray analyses of BAL cells from 3 CR asthmatics showed significantly higher levels ($p < 0.05$) of TNF-alpha, TNF-alpha-induced protein 3, early growth response 1, dual specificity phosphatase 2, and molecule possessing ankyrin repeats (8.9-, 4.9-, 12.5-, 10.5-, 7.2-fold increase, respectively) as compared to 3 CS asthmatics, identifying activation of LPS responsive genes. Ten CR asthmatics had significantly higher amounts ($p < 0.01$) of LPS in BAL fluid than 8 CS asthmatics (1444 ± 457 pg versus 271 ± 216 pg per mg/ml of total protein). Since dogs are a significant source of LPS, we assessed dog ownership and found that 67% (12/18) of CR asthmatics lived with a dog versus 37.5% (6/16) of CS asthmatics ($p < 0.05$). Dog allergy was present in 72.2% of CR and 31.3% of CS asthmatics ($p < 0.01$). 24h stimulation of murine BAL macrophages with LPS resulted in loss of the ability of dexamethasone to suppress TNF-alpha production.

CONCLUSIONS: High LPS exposure by living with a dog may contribute to activation of LPS responsive genes, resulting in CR asthma.

National Jewish Health is the leading respiratory hospital in the nation. Founded 120 years ago as a nonprofit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to groundbreaking medical research and treatment of patients with respiratory, cardiac, immune and related disorders. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care. To learn more, visit the media resources page.

Media Contacts

Our team is available to arrange interviews, discuss events and story ideas.

William Allstetter

Adam Dormuth

303.398.1002
allstetterw@njhealth.org

303.398.1082
dormutha@njhealth.org